Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Spencer describes a phased plan where patients receive first bispecific doses at a tertiary center and then transfer back to the community. Jennifer and Alex note CRS is mostly front-loaded, with delayed events rare beyond early doses. This model reduces community safety burden, but the community still must handle later fevers.

Related Insights

Prophylactically administering tocilizumab before bispecific antibody treatment can slash the incidence of cytokine release syndrome (CRS) from ~75% down to 20%. This simple intervention, analogous to using G-CSF for neutropenia, mitigates side effects and makes outpatient administration a much safer and more feasible option for patients.

Administering tocilizumab before the first bispecific antibody dose significantly reduces Cytokine Release Syndrome (CRS) risk. This proactive strategy enables safer outpatient treatment, lowering hospital admissions and improving patient access, especially in community settings.

The acute toxicity risk during the initial ramp-up phase of bispecific antibodies (like CRS and ICANS) makes them challenging to manage in a typical community oncology setting. A safer model involves academic centers managing the high-risk initiation period before transitioning the patient back to their community provider for ongoing care.

Advanced SCLC therapies like the bispecific antibody tarlatumab require inpatient administration for the first two doses to manage severe side effects like Cytokine Release Syndrome (CRS). Many community centers lack the specialized cellular therapeutics or transplant teams necessary for this complex monitoring, creating an implementation gap.

A modified three-step-up dosing schedule for epcoritamab drastically reduced cytokine release syndrome (CRS) rates to 26%, with no severe events. This safety profile supports fully outpatient administration, making this highly effective regimen accessible to community practices without immediate hospital access.

The IntentiMig trial showed that proactively administering tocilizumab with a bispecific antibody resulted in a zero percent incidence of cytokine release syndrome (CRS). This safety improvement could be pivotal for the broader adoption of bispecifics in community oncology settings, which are less equipped to manage severe side effects.

Spencer, at Lynn Cancer Institute, says his committee had to update multiple EMRs, teach ER doctors, ICU staff, residents and hospitalists about CRS, ensure tocilizumab is available after hours, and secure STAT CMP testing. He describes the coordination across stakeholders as very difficult and the main operational barrier to launching bispecifics.

While initial doses of the BiTE therapy tarlatumab require inpatient monitoring for CRS and ICANS, experienced centers are shifting to outpatient administration for subsequent cycles. This is typically for low-risk patients with good support who live nearby, signaling a move towards more manageable community use.

Giving prophylactic tocilizumab before bispecific antibody administration is a highly effective strategy to mitigate Cytokine Release Syndrome (CRS). This approach can reduce CRS rates from ~70% to 5-14%, making outpatient step-up dosing a much more feasible and safer option for community oncology centers.

Clinicians often conflate bispecific cytokine release syndrome with CAR-T CRS, creating undue reluctance in community settings. Bispecific grade 1 CRS typically presents with mild fevers (around 101°F) that rarely escalate into high-grade fevers (103°F–104°F) seen in CAR-T. In most cases, bispecific grade 1 CRS is safely controlled in the outpatient setting with acetaminophen, ibuprofen, or a single dose of oral dexamethasone.